Indazole

Indazole

SCHEMBL1854887

NC(=O)O.c1ccc2[nH]ncc2c1

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.73
IDO1 P14902 1/20 0.73
CDK2 P24941 1/20 0.73
ABCB1 P08183 1/20 0.63
ROCK1 Q13464 5/20 0.50
ROCK2 O75116 4/20 0.50
FGFR1 P11362 2/20 0.50
CDK5 Q00535 2/20 0.50
CLK4 Q9HAZ1 2/20 0.50
DYRK1B Q9Y463 2/20 0.50
PLK4 O00444 1/20 0.50
CHEK1 O14757 1/20 0.50
AURKA O14965 1/20 0.50
DAPK3 O43293 1/20 0.50
MAP4K4 O95819 1/20 0.50
CSF1R P07333 1/20 0.50
RET P07949 1/20 0.50
PDGFRA P16234 1/20 0.50
LTK P29376 1/20 0.50
KDR P35968 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indazole SCHEMBL4408711 0.94 HSP90AA1 (0.76) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL8415085 0.92 HSP90AA1 (0.79) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL5746975 0.91 HSP90AA1 (0.70) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL28043445 0.90 HSP90AA1 (0.76) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL1162915 0.90 HSP90AA1 (0.76) HSP90AA1IDO1CDK2ABCB1ROCK1
Benzamide SCHEMBL17674075 0.90 HSP90AA1 (0.63) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL1574644 0.89 HSP90AA1 (0.73) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL2029058 0.89 HSP90AA1 (0.73) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL27865905 0.89 HSP90AA1 (0.73) HSP90AA1IDO1CDK2ABCB1ROCK1
Indazole SCHEMBL7371212 0.88 HSP90AA1 (0.95) HSP90AA1IDO1CDK2ABCB1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487116-B2 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBVIE INC. (US) 2013-07-16 US disclosed
CN-102617464-A fused compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor ABBOTT LAB 2012-08-01 CN disclosed
US-20120190845-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBVIE INC. 2012-07-26 US disclosed
US-8071762-B2 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LABORATORIES (US) 2011-12-06 US disclosed
EP-2017265-B1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LAB (US) 2011-05-25 EP disclosed
CN-101445501-A Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LAB (US) 2009-06-03 CN disclosed
EP-2017265-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor Abbott Laboratories (US) 2009-01-21 EP disclosed
US-20080287676-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2008-11-20 US disclosed
EP-1658269-B1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LAB (US) 2008-10-22 EP disclosed
US-7375126-B2 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LABORATORIES (US) 2008-05-20 US disclosed
CN-1835924-A Fused compounds that inhibit vanilloid receptor subtype 1(vr1) receptor ABBOTT LAB (US) 2006-09-20 CN disclosed
EP-1658269-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR Abbott Laboratories (US) 2006-05-24 EP disclosed
US-20050043351-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBVIE INC. 2005-02-24 US disclosed
WO-2004111009-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ABBOTT LABORATORIES (US) 2004-12-23 WO disclosed
EP-0538000-A1 Indole and indazole carbamates as leukotriene antagonists MERCK FROSST CANADA, INC. (CA) 1993-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287676-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ARRB1, TRPV1, TRPV5 HSP90AA1 4671/4885IDO1 3899/4885CDK2 1708/4885
US-20050043351-A1 Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ARRB1, TRPV1, TRPV5 HSP90AA1 4690/4885IDO1 3892/4885CDK2 1644/4885
US-20120190845-A1 FUSED COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR ARRB1, TRPV1, TRPV5 HSP90AA1 4671/4885IDO1 3899/4885CDK2 1708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.